
Ardelyx ARDX
$ 6.47
-1.22%
Annual report 2025
added 02-19-2026
Ardelyx Interest Expense 2011-2026 | ARDX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Ardelyx
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 4.5 M | 5.1 M | 5.73 M | 3.53 M | - | - | -261 K | 10 K | -52 K | -30 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.73 M | -261 K | 2.32 M |
Quarterly Interest Expense Ardelyx
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 2.36 M | - | 1.11 M | 1.08 M | 1.03 M | - | 886 K | 777 K | 746 K | - | 1.22 M | 1.2 M | 1.1 M | - | 1.2 M | 1.23 M | 1.36 M | - | 1.44 M | 1.45 M | 1.43 M | - | 1.4 M | 692 K | 670 K | - | 501 K | 697 K | - | - | - | 77 K | 62 K | - | -77 K | -49 K | -12 K | - | -7 K | -8 K | -4 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.36 M | -77 K | 812 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Apellis Pharmaceuticals
APLS
|
-133 K | $ 20.7 | -1.24 % | $ 2.61 B | ||
|
Axsome Therapeutics
AXSM
|
-15.9 M | $ 166.38 | - | $ 8.28 B | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
AbCellera Biologics
ABCL
|
-2.71 M | $ 3.82 | - | $ 1.14 B | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | ||
|
Capricor Therapeutics
CAPR
|
399 K | $ 26.86 | -3.83 % | $ 719 M | ||
|
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
476 K | - | - | $ 2.17 B | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
AgeX Therapeutics
AGE
|
4.9 M | - | -10.17 % | $ 12.2 K | ||
|
Codexis
CDXS
|
-10.4 M | $ 1.02 | - | $ 74.9 M | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
1.26 M | $ 3.34 | 0.3 % | $ 1.2 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Agios Pharmaceuticals
AGIO
|
1.96 M | $ 29.2 | -3.41 % | $ 1.69 B | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
Cellectis S.A.
CLLS
|
371 K | $ 3.8 | -2.06 % | $ 116 M | ||
|
Alector
ALEC
|
13.2 M | $ 2.21 | -9.05 % | $ 228 M | ||
|
Allena Pharmaceuticals
ALNA
|
-38 K | - | 3.16 % | $ 1.9 M | ||
|
Aileron Therapeutics
ALRN
|
685 K | - | 10.36 % | $ 9.8 M | ||
|
Altimmune
ALT
|
48 K | $ 4.16 | - | $ 295 M | ||
|
AlloVir
ALVR
|
1.19 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-5.01 K | - | -11.43 % | $ 502 K | ||
|
Amarin Corporation plc
AMRN
|
7 K | $ 13.93 | 0.94 % | $ 5.78 B | ||
|
AbbVie
ABBV
|
2.89 B | $ 234.26 | 0.94 % | $ 414 B | ||
|
Blueprint Medicines Corporation
BPMC
|
656 K | - | - | $ 8.14 B | ||
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | ||
|
AIM ImmunoTech
AIM
|
629 K | $ 0.77 | -14.64 % | $ 37 M |